Rechanneling the Current Cardiac Risk Paradigm: Arrhythmia Risk Assessment During Drug Development Without the Thorough QT Study
July 23, 2013
Silver Spring, Maryland, USA
The mission of the HESI Cardiac Safety Committee is to improve public health by reducing unanticipated cardiovascular-related adverse effects from drugs or chemicals, and to develop innovative approaches to support early detection and prediction as well as improved understanding of cardiovascular toxicology and pathobiology.
National Institute of Environmental Health Sciences, National Toxicology Program
US Food and Drug Administration
July 23, 2013
Silver Spring, Maryland, USA
March 18, 2013 – March 19, 2013
Cambridge, Massachusetts, USA
This workshop was co-sponsored by co-sponsored by the HESI Cardiac Safety Technical Committee and the Safety Pharmacology Society.
October 4, 2012
Phoenix, Arizona, USA
This event was sponsored by the HESI Technical Committee on Cardiac Safety.
October 6, 2008 – October 7, 2008
Washington, DC, USA
This event was sponsored by the HESI Cardiac Safety Committee.
September 22, 2008 – September 25, 2008
Madison, Wisconsin, USA
The HESI Cardiac Safety Technical Committee presented gave two presentations (“A HESI Consortium Approach to Assess the Human Predictive Value of Non-Clinical Repolarization Assays") at this event.
February 14, 2008 – February 15, 2008
Washington, DC, USA
This workshop was sponsored by the HESI Biomarkers of Toxicity Committee.
British Journal of Pharmacology, 2017
The strengths and limitations of three nonclinical repolarization assays used to define the risk of clinical drug-induced delayed ventricular repolarization (a surrogate marker of the rare but potentially lethal arrhythmia Torsades de Pointes) were compared during a retrospective analysis of an anonymized database of 150 ...
Journal of Pharmacological and Toxicological Methods, 2017
Heart rate correction methods are frequently used when analyzing data collected during the drug development process to better understand the QT interval. There is variability in this methodology and the optimal heart rate correction formula is often debated. This paper details a study that explored the ...
PLOS One, 2017
This article characterizes a time course model of inflammation and hemostatic activation in rats treated with bacterial endotoxin (lipopolysaccharide, LPS) through a combination of traditional histologic and clinicopathologic endpoints and analyses of novel circulating biomarkers, including microRNA (miRNA) and ...
Journal of Pharmacological and Toxicological Methods, 2017
The importance of drug-induced effects on the inotropic state of the heart is well known. Unlike hemodynamic and cardiac electrophysiological methods, which have been routinely used in drug safety testing for years, the non-clinical assessment of drug effects on myocardial contractility is used less frequently with ...
Science Translational Medicine, 2016
Advances in cancer therapy has resulted in more cancer survivors, and now quality of life throughout treatment and surviving years is becoming a new focus for the scientific community. There are often unintended toxicities related to cancer therapies. HESI established the THRIVE program to address quality-of-life research.
Journal of Pharmacological and Toxicological Methods, 2016
The implementation of the ICH S7B and E14 guidelines has been successful in preventing the introduction of potentially torsadogenic drugs to the market, but it has also unduly constrained drug development by focusing on hERG block and QT prolongation as essential determinants of proarrhythmia risk.
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-3859
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.